Guide to Drug Financing Mechanisms
(1998; 64 pages) [French] [Spanish]
Table of Contents
View the documentForeword
View the documentAcknowledgements
Open this folder and view contentsIntroduction
Close this folderChapter 1. Selection
Close this folderObjective of selection
View the documentAvoid drugs of no therapeutic interest
View the documentReduce the number of drugs
View the documentIncrease the efficiency of available drugs
Open this folder and view contentsThe criterion of economic efficiency
View the documentSelection: important points
Open this folder and view contentsChapter 2. Procurement
Open this folder and view contentsChapter 3. Distribution
Open this folder and view contentsChapter 4. Prescribing
Open this folder and view contentsSummary: contributions and limitations of the economic approach
View the documentReferences
View the documentSelected WHO publications of related interest
View the documentBack cover
 

Increase the efficiency of available drugs

From a public health standpoint, the selection of drugs should be based in the first instance on efficacy, safety and sufficient quality, and only then on cost. The economic standpoint differs. It uses only one criterion for the classification of all drugs-efficiency. Efficiency is the ratio of costs to efficacy (including the desired therapeutic effects and the risks inherent in any given quality). While the most effective and least expensive drugs are preferred from the twin standpoints of public health and the economy, the criterion of economic efficiency discriminates between more effective drugs that cost more and less effective drugs that cost less.

to previous section to next section
 

Last updated: May 3, 2013